<DOC>
	<DOC>NCT00232999</DOC>
	<brief_summary>This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.</brief_summary>
	<brief_title>Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Mild stable allergic asthma Positive skinprick test to at least one common aeroallergen Positive methacholine challenge Positive allergeninduced early and latephase airway bronchoconstriction General good health Lung diseases other than mild allergic asthma History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease Chronic use of asthma medications other than short or intermediate betaagonists or ipratropium Use of tobacco products within one year starting study or smoking history &gt;10 pack years If female, pregnant or lactating or have positive pregnancy test at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Allergic asthma</keyword>
	<keyword>Allergen challenge</keyword>
	<keyword>Bronchial hyperresponsiveness</keyword>
</DOC>